Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record of 5 Candidate Drugs delivered in 5 years.
Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.
Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 and a number of epigenetics related lysine methyltransferases.
No reviews to display
Domainex Programme Shows Great Promise for the Treatment of Inflammatory Diseases, Such as Chronic Obstructive Pulmonary Disease (COPD)
07 Apr 2014
University of Warwick Wins Domainex’s First Discovery STAR Award to Support Hunt for New Chagas Disease Treatment
02 Sep 2013
18 Feb 2013
25 Jan 2013
Domainex Researchers Identify Small-Molecule Inhibitors of TBK1/IKKepsilon Affecting IL-17 Signaling
05 Nov 2012